TY - JOUR
T1 - Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation
AU - Kamimura, Tomohiko
AU - Miyamoto, Toshihiro
AU - Kawano, Noriaki
AU - Numata, Akihiko
AU - Ito, Yoshikiyo
AU - Chong, Yong
AU - Nagafuji, Koji
AU - Teshima, Takanori
AU - Hayashi, Shin
AU - Akashi, Koichi
N1 - Funding Information:
Acknowledgments We thank the nursing staff who cared for the patients at the Harasanshin Hospital and Kyushu University Hospital. This work was supported, in part, by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (23390254 to T.M.).
PY - 2012/6
Y1 - 2012/6
N2 - Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive hematologic neoplasm that has an extremely poor prognosis; however, this has improved following recent progress in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Several clinical studies have shown that discontinuation of immunosuppressant therapy induces durable remission in a significant number of post-transplant relapsed patients, suggesting that ATLL may be susceptible to a graft-versus-leukemia effect. Here, we report two cases with ATLL who received donor lymphocyte infusions (DLIs) for relapse after allo-HSCT; one patient achieved complete remission (CR) after a single DLI, and the other suffered repeated relapses and was treated with chemotherapy and radiotherapy combined with a total of five rounds of DLIs. Both patients presented with exacerbation of the graft-versus-host disease after the DLIs, and remained in CR for 9 and 8 years, respectively. These data support the use of DLIs as an effective therapy to induce durable CR in the treatment of relapsed ATLL. In this study, we review previous reports and discuss the role of DLIs in the treatment of post-transplant relapsed ATLL.
AB - Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive hematologic neoplasm that has an extremely poor prognosis; however, this has improved following recent progress in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Several clinical studies have shown that discontinuation of immunosuppressant therapy induces durable remission in a significant number of post-transplant relapsed patients, suggesting that ATLL may be susceptible to a graft-versus-leukemia effect. Here, we report two cases with ATLL who received donor lymphocyte infusions (DLIs) for relapse after allo-HSCT; one patient achieved complete remission (CR) after a single DLI, and the other suffered repeated relapses and was treated with chemotherapy and radiotherapy combined with a total of five rounds of DLIs. Both patients presented with exacerbation of the graft-versus-host disease after the DLIs, and remained in CR for 9 and 8 years, respectively. These data support the use of DLIs as an effective therapy to induce durable CR in the treatment of relapsed ATLL. In this study, we review previous reports and discuss the role of DLIs in the treatment of post-transplant relapsed ATLL.
UR - http://www.scopus.com/inward/record.url?scp=84865026041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865026041&partnerID=8YFLogxK
U2 - 10.1007/s12185-012-1056-3
DO - 10.1007/s12185-012-1056-3
M3 - Article
C2 - 22481502
AN - SCOPUS:84865026041
SN - 0925-5710
VL - 95
SP - 725
EP - 730
JO - International journal of hematology
JF - International journal of hematology
IS - 6
ER -